Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketorolac + ibuprofen is a combination of two nonsteroidal anti-inflammatory drugs (NSAIDs): ketorolac and ibuprofen. Both agents act by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), leading to decreased synthesis of prostaglandins, which are mediators of pain, inflammation, and fever. Ketorolac is typically used for short-term management of moderate to severe pain, often postoperatively, while ibuprofen is widely used for mild to moderate pain and inflammation. Combining these two NSAIDs does not provide additional analgesic benefit but significantly increases the risk of serious adverse effects such as gastrointestinal bleeding, ulceration, kidney damage, and other NSAID-related toxicities. Clinical guidelines strongly advise against the concurrent use of ketorolac with other NSAIDs like ibuprofen due to these risks[1][2][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketorolac + ibuprofen.